Premium
Oxcarbazepine disposition: Preliminary observations in patients
Author(s) -
Kumps A.,
Wurth C.
Publication year - 1990
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bdd.2510110405
Subject(s) - oxcarbazepine , disposition , pharmacokinetics , medicine , pharmacology , psychology , epilepsy , psychiatry , carbamazepine , social psychology
We describe a preliminary retrospective study based on the concentration of two hydroxylated metabolites of oxcarbazepine (OCZ), a new anticonvulsant substance, measured in the plasma of 15 patients with epilepsy. Their ages ranged from 8 to 68 years. 6 of them also received phenobarbital and/or phenytoin as co‐medication. The concentration of 10‐hydroxy‐10,11‐dihydrocarbamazepine (HCBZ) or of trans‐10,11‐dihydroxy‐10,11‐dihydrocarbamazepine (DHCBZ), the metabolites measured, are significantly correlated with the dose of OCZ ( p < 0·05 and p < 0·01, respectively). DHCBZ concentrations, standardized to a constant OCZ dose or to a constant HCBZ concentration, are significantly higher during co‐medication ( p < 0·01 and p < 0·05, respectively); HCBZ levels are unaffected. These results confirm that enzyme‐inducing drugs, although accelerating the oxidation HCBZ, do not induce its formation. Since HCBZ is the active metabolite, such drug interaction seems unlikely to alter OCZ pharmacological activity.